Vericel Corp (NASDAQ:VCEL)

27.40
Delayed Data
As of 3:59pm ET
 -2.44 / -8.18%
Today’s Change
22.42
Today|||52-Week Range
60.24
-30.28%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$1.4B

Company Description

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Contact Information

Vericel Corp.
64 Sidney Street
Cambridge Massachusetts 02139-4170
P:(617) 588-5555
Investor Relations:

Employees

Shareholders

Mutual fund holders64.64%
Individual stakeholders5.92%
Other institutional47.12%

Top Executives

Dominick C. ColangeloPresident, Chief Executive Officer & Director
Michael HalpinChief Operating Officer
Joseph A. MaraChief Financial Officer & Treasurer
Jonathan Mark HopperChief Medical Officer
Sean C. FlynnSecretary, Senior Vice President & General Counsel